Form 4: Amicus Therapeutics Officer Sells Shares

Amicus Therapeutics' Chief Legal Officer, Ellen Rosenberg, executed pre-planned stock option exercises and subsequent sales of common stock.

Summary

• Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, Inc. (FOLD), engaged in a series of transactions involving the company's common stock.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 10, 2024.
• On November 24, 2025, Rosenberg exercised options to acquire 25,000 shares at $6.10 per share and 11,000 shares at $5.13 per share.
• On the same day, she sold 36,000 shares of common stock at a weighted average price of $10.063, with prices ranging from $10.00 to $10.31.
• On November 25, 2025, Rosenberg exercised options to acquire 36,000 shares at $5.13 per share and subsequently sold 36,000 shares at $10.00 per share.
• On November 26, 2025, she exercised options to acquire 23,621 shares at $5.13 per share and sold 23,621 shares at $10.00 per share.
• All options exercised were fully vested and exercisable as of their respective transaction dates.
• Following these transactions, Rosenberg directly beneficially owns 507,710 shares of common stock and indirectly owns 15,000 shares through her spouse.

Sentiment

Score: 6

Explanation: The filing details routine, pre-planned insider transactions (option exercises and sales) by a Chief Legal Officer. While a sale reduces insider ownership, the pre-scheduled nature under a 10b5-1 plan suggests a liquidity event rather than a change in company fundamentals, leading to a neutral to slightly positive sentiment due to the profitable execution.

Positives

• The sale prices for the common stock ($10.00 $10.31) were significantly higher than the exercise prices of the options ($5.13 $6.10), indicating a profitable transaction for the reporting person.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, suggesting a planned liquidity event rather than a reaction to recent company performance.

Negatives

• The Chief Legal Officer reduced her direct beneficial ownership of common stock by a net of 95,621 shares through these transactions.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: A reduction in direct insider ownership, but this is a pre-planned transaction under a 10b5-1 plan, which typically has less impact on market sentiment than unscheduled sales.

Key Dates

Recommendation

The Form 4 details pre-scheduled insider transactions (option exercises and sales) by a Chief Legal Officer under a Rule 10b5-1 plan. These are routine liquidity events and do not typically signal a change in the company's fundamental prospects or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as no new material information impacting the company's valuation is presented.

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Options, Share Sale, Ellen Rosenberg, Chief Legal Officer, 10b5-1 Plan, Beneficial Ownership